DiamiR Biosciences has announced a partnership with JADBio to leverage machine learning technology in the development of diagnostic tests for brain health and diseases such as Alzheimer’s and Rett syndrome. The collaboration will utilize JADBio’s Automated Machine Learning (AutoML) Platform and Services to create predictive models based on DiamiR’s microRNA panels and other factors for risk assessment. This partnership marks a significant milestone in DiamiR’s validation efforts for its diagnostic tests.
DiamiR’s CEO, Alidad Mireskandari, Ph.D., expressed enthusiasm about incorporating machine learning capabilities into their microRNA platform, stating that it is a crucial step towards validating their diagnostic tests. By partnering with JADBio, a leader in Automated Machine Learning in life sciences, DiamiR aims to develop advanced ML-based testing algorithms to further advance their development efforts.
JADBio’s CEO, Pavlos Charonyktakis, expressed excitement about the collaboration, emphasizing their confidence in JADBio’s state-of-the-art ML platform and services to support DiamiR in efficiently validating their biomarker panels and developing highly accurate diagnostic tests.
DiamiR is a privately held molecular diagnostics company that focuses on developing minimally invasive tests for the detection and monitoring of pathology. Their approach involves quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, disease progression, and treatment monitoring. DiamiR collaborates with renowned academic centers, disease foundations, and biopharmaceutical companies.
JADBio, on the other hand, is an AutoML-based Bioinformatics platform that enables life scientists to make novel biomarker discoveries and build unique predictive models. Their platform eliminates the need for coding or ML expertise, allowing bioinformaticians and data scientists to analyze various biomolecular data types effortlessly. JADBio offers features such as image analysis, batch analysis, and the incorporation of the SciKit Learn algorithm through their API.
This partnership between DiamiR and JADBio holds immense promise in advancing the field of diagnostic testing for brain health. By leveraging machine learning technology, these companies aim to enhance the accuracy and efficiency of diagnostic tests, ultimately benefiting patients affected by diseases like Alzheimer’s and Rett syndrome.
For more information about DiamiR, please visit their website at www.diamirbio.com. Likewise, to learn more about JADBio and their AutoML-based Bioinformatics platform, visit jadbio.com.
